nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP3A4—prostate cancer	0.109	1	CbGaD
Loperamide—CYP2C8—Nilutamide—prostate cancer	0.037	0.0747	CbGbCtD
Loperamide—CYP2C8—Abiraterone—prostate cancer	0.0307	0.0619	CbGbCtD
Loperamide—CYP2B6—Estrone—prostate cancer	0.0293	0.0591	CbGbCtD
Loperamide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0286	0.0577	CbGbCtD
Loperamide—CYP2B6—Ethinyl Estradiol—prostate cancer	0.0261	0.0527	CbGbCtD
Loperamide—CYP2D6—Bicalutamide—prostate cancer	0.0236	0.0476	CbGbCtD
Loperamide—ABCB1—Estramustine—prostate cancer	0.0233	0.047	CbGbCtD
Loperamide—CYP2C8—Cabazitaxel—prostate cancer	0.0227	0.0458	CbGbCtD
Loperamide—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0198	0.0399	CbGbCtD
Loperamide—CYP2D6—Abiraterone—prostate cancer	0.0196	0.0395	CbGbCtD
Loperamide—ABCB1—Cabazitaxel—prostate cancer	0.0154	0.031	CbGbCtD
Loperamide—CYP3A4—Bicalutamide—prostate cancer	0.015	0.0303	CbGbCtD
Loperamide—ABCB1—Estrone—prostate cancer	0.015	0.0303	CbGbCtD
Loperamide—CYP3A4—Estramustine—prostate cancer	0.014	0.0282	CbGbCtD
Loperamide—ABCB1—Ethinyl Estradiol—prostate cancer	0.0134	0.027	CbGbCtD
Loperamide—CYP2C8—Estradiol—prostate cancer	0.0127	0.0257	CbGbCtD
Loperamide—CYP3A4—Abiraterone—prostate cancer	0.0124	0.0251	CbGbCtD
Loperamide—CYP3A4—Flutamide—prostate cancer	0.0124	0.0251	CbGbCtD
Loperamide—POMC—urine—prostate cancer	0.0114	0.204	CbGeAlD
Loperamide—ABCB1—Conjugated Estrogens—prostate cancer	0.00983	0.0198	CbGbCtD
Loperamide—CYP3A4—Cabazitaxel—prostate cancer	0.00921	0.0186	CbGbCtD
Loperamide—CYP3A4—Estrone—prostate cancer	0.009	0.0181	CbGbCtD
Loperamide—ABCB1—Mitoxantrone—prostate cancer	0.00893	0.018	CbGbCtD
Loperamide—ABCB1—Estradiol—prostate cancer	0.00863	0.0174	CbGbCtD
Loperamide—CYP2C8—Etoposide—prostate cancer	0.00832	0.0168	CbGbCtD
Loperamide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00802	0.0162	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—prostate cancer	0.00749	0.0151	CbGbCtD
Loperamide—ABCB1—Prednisone—prostate cancer	0.00742	0.015	CbGbCtD
Loperamide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00589	0.0119	CbGbCtD
Loperamide—ABCB1—Etoposide—prostate cancer	0.00563	0.0114	CbGbCtD
Loperamide—CYP3A4—Mitoxantrone—prostate cancer	0.00535	0.0108	CbGbCtD
Loperamide—CYP3A4—Estradiol—prostate cancer	0.00517	0.0104	CbGbCtD
Loperamide—ABCB1—Docetaxel—prostate cancer	0.00515	0.0104	CbGbCtD
Loperamide—CALM2—semen—prostate cancer	0.00446	0.0797	CbGeAlD
Loperamide—CYP3A4—Prednisone—prostate cancer	0.00444	0.00896	CbGbCtD
Loperamide—CALM1—semen—prostate cancer	0.00444	0.0794	CbGeAlD
Loperamide—ABCB1—Doxorubicin—prostate cancer	0.00384	0.00775	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—prostate cancer	0.00362	0.0073	CbGbCtD
Loperamide—CYP3A4—Etoposide—prostate cancer	0.00338	0.00681	CbGbCtD
Loperamide—CYP3A4—Docetaxel—prostate cancer	0.00309	0.00623	CbGbCtD
Loperamide—POMC—renal system—prostate cancer	0.00279	0.0499	CbGeAlD
Loperamide—CYP3A4—Doxorubicin—prostate cancer	0.0023	0.00464	CbGbCtD
Loperamide—OPRK1—prostate gland—prostate cancer	0.00216	0.0387	CbGeAlD
Loperamide—POMC—testis—prostate cancer	0.0018	0.0322	CbGeAlD
Loperamide—CYP3A4—urine—prostate cancer	0.00175	0.0312	CbGeAlD
Loperamide—CACNA1A—testis—prostate cancer	0.00172	0.0308	CbGeAlD
Loperamide—CYP2D6—urine—prostate cancer	0.00172	0.0308	CbGeAlD
Loperamide—OPRD1—renal system—prostate cancer	0.00154	0.0275	CbGeAlD
Loperamide—CALM3—prostate gland—prostate cancer	0.00142	0.0254	CbGeAlD
Loperamide—CALM3—seminal vesicle—prostate cancer	0.0012	0.0215	CbGeAlD
Loperamide—CALM2—prostate gland—prostate cancer	0.00112	0.02	CbGeAlD
Loperamide—CALM1—prostate gland—prostate cancer	0.00111	0.0199	CbGeAlD
Loperamide—CALM3—urethra—prostate cancer	0.000953	0.017	CbGeAlD
Loperamide—CALM2—seminal vesicle—prostate cancer	0.000945	0.0169	CbGeAlD
Loperamide—CALM2—epithelium—prostate cancer	0.000821	0.0147	CbGeAlD
Loperamide—CALM1—epithelium—prostate cancer	0.000817	0.0146	CbGeAlD
Loperamide—CALM2—renal system—prostate cancer	0.000762	0.0136	CbGeAlD
Loperamide—CALM1—renal system—prostate cancer	0.000758	0.0136	CbGeAlD
Loperamide—CALM2—urethra—prostate cancer	0.000748	0.0134	CbGeAlD
Loperamide—CALM1—urethra—prostate cancer	0.000745	0.0133	CbGeAlD
Loperamide—CALM3—bone marrow—prostate cancer	0.000733	0.0131	CbGeAlD
Loperamide—OPRM1—testis—prostate cancer	0.000678	0.0121	CbGeAlD
Loperamide—Haloperidol—CBR1—prostate cancer	0.000668	0.149	CrCbGaD
Loperamide—CYP2C8—renal system—prostate cancer	0.000631	0.0113	CbGeAlD
Loperamide—CALM3—testis—prostate cancer	0.000627	0.0112	CbGeAlD
Loperamide—CALM2—bone marrow—prostate cancer	0.000576	0.0103	CbGeAlD
Loperamide—CALM1—bone marrow—prostate cancer	0.000573	0.0103	CbGeAlD
Loperamide—CYP2B6—renal system—prostate cancer	0.000566	0.0101	CbGeAlD
Loperamide—CALM2—testis—prostate cancer	0.000492	0.0088	CbGeAlD
Loperamide—CALM1—testis—prostate cancer	0.00049	0.00876	CbGeAlD
Loperamide—CALM3—lymph node—prostate cancer	0.000454	0.00813	CbGeAlD
Loperamide—ABCB1—prostate gland—prostate cancer	0.000444	0.00794	CbGeAlD
Loperamide—CYP3A4—renal system—prostate cancer	0.000428	0.00765	CbGeAlD
Loperamide—CYP2D6—renal system—prostate cancer	0.000421	0.00752	CbGeAlD
Loperamide—CYP2C8—testis—prostate cancer	0.000408	0.0073	CbGeAlD
Loperamide—Tamoxifen—SULT1A1—prostate cancer	0.000408	0.091	CrCbGaD
Loperamide—ABCB1—seminal vesicle—prostate cancer	0.000376	0.00672	CbGeAlD
Loperamide—CYP2B6—testis—prostate cancer	0.000366	0.00654	CbGeAlD
Loperamide—CALM2—lymph node—prostate cancer	0.000357	0.00638	CbGeAlD
Loperamide—CALM1—lymph node—prostate cancer	0.000355	0.00635	CbGeAlD
Loperamide—ABCB1—epithelium—prostate cancer	0.000326	0.00583	CbGeAlD
Loperamide—ABCB1—renal system—prostate cancer	0.000303	0.00541	CbGeAlD
Loperamide—ABCB1—urethra—prostate cancer	0.000297	0.00532	CbGeAlD
Loperamide—CYP2D6—testis—prostate cancer	0.000272	0.00486	CbGeAlD
Loperamide—Clotrimazole—CYP17A1—prostate cancer	0.000255	0.057	CrCbGaD
Loperamide—ABCB1—bone marrow—prostate cancer	0.000229	0.00409	CbGeAlD
Loperamide—ABCB1—testis—prostate cancer	0.000196	0.0035	CbGeAlD
Loperamide—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000188	0.0013	CcSEcCtD
Loperamide—Dry mouth—Estradiol—prostate cancer	0.000188	0.0013	CcSEcCtD
Loperamide—Dizziness—Ethinyl Estradiol—prostate cancer	0.000186	0.00129	CcSEcCtD
Loperamide—Urticaria—Goserelin—prostate cancer	0.000184	0.00127	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000184	0.00127	CcSEcCtD
Loperamide—Anaphylactic shock—Estradiol—prostate cancer	0.000184	0.00127	CcSEcCtD
Loperamide—Abdominal pain—Goserelin—prostate cancer	0.000183	0.00127	CcSEcCtD
Loperamide—Urticaria—Conjugated Estrogens—prostate cancer	0.000183	0.00126	CcSEcCtD
Loperamide—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000182	0.00125	CcSEcCtD
Loperamide—Immune system disorder—Etoposide—prostate cancer	0.000181	0.00125	CcSEcCtD
Loperamide—Abdominal distension—Prednisone—prostate cancer	0.000181	0.00125	CcSEcCtD
Loperamide—Nervous system disorder—Estradiol—prostate cancer	0.00018	0.00125	CcSEcCtD
Loperamide—Vomiting—Ethinyl Estradiol—prostate cancer	0.000179	0.00124	CcSEcCtD
Loperamide—Skin disorder—Estradiol—prostate cancer	0.000179	0.00123	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000178	0.00123	CcSEcCtD
Loperamide—Rash—Ethinyl Estradiol—prostate cancer	0.000178	0.00123	CcSEcCtD
Loperamide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000178	0.00123	CcSEcCtD
Loperamide—Toremifene—ESR1—prostate cancer	0.000177	0.0395	CrCbGaD
Loperamide—Discomfort—Mitoxantrone—prostate cancer	0.000177	0.00122	CcSEcCtD
Loperamide—Headache—Ethinyl Estradiol—prostate cancer	0.000177	0.00122	CcSEcCtD
Loperamide—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000171	0.00118	CcSEcCtD
Loperamide—Hypersensitivity—Goserelin—prostate cancer	0.000171	0.00118	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—prostate cancer	0.00017	0.00117	CcSEcCtD
Loperamide—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000169	0.00117	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—prostate cancer	0.000168	0.00116	CcSEcCtD
Loperamide—Nausea—Ethinyl Estradiol—prostate cancer	0.000167	0.00116	CcSEcCtD
Loperamide—Asthenia—Goserelin—prostate cancer	0.000166	0.00115	CcSEcCtD
Loperamide—Skin disorder—Mitoxantrone—prostate cancer	0.000166	0.00115	CcSEcCtD
Loperamide—Asthenia—Conjugated Estrogens—prostate cancer	0.000165	0.00114	CcSEcCtD
Loperamide—Urinary tract disorder—Docetaxel—prostate cancer	0.000165	0.00114	CcSEcCtD
Loperamide—Pruritus—Goserelin—prostate cancer	0.000164	0.00113	CcSEcCtD
Loperamide—Somnolence—Estradiol—prostate cancer	0.000163	0.00113	CcSEcCtD
Loperamide—Urethral disorder—Docetaxel—prostate cancer	0.000163	0.00113	CcSEcCtD
Loperamide—Pruritus—Conjugated Estrogens—prostate cancer	0.000163	0.00112	CcSEcCtD
Loperamide—Dyspepsia—Estradiol—prostate cancer	0.000162	0.00112	CcSEcCtD
Loperamide—Urinary tract disorder—Capecitabine—prostate cancer	0.000159	0.0011	CcSEcCtD
Loperamide—Gastrointestinal disorder—Estradiol—prostate cancer	0.000159	0.0011	CcSEcCtD
Loperamide—Diarrhoea—Goserelin—prostate cancer	0.000159	0.0011	CcSEcCtD
Loperamide—Fatigue—Estradiol—prostate cancer	0.000159	0.00109	CcSEcCtD
Loperamide—Urethral disorder—Capecitabine—prostate cancer	0.000158	0.00109	CcSEcCtD
Loperamide—Erythema multiforme—Docetaxel—prostate cancer	0.000158	0.00109	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—prostate cancer	0.000157	0.00109	CcSEcCtD
Loperamide—Constipation—Estradiol—prostate cancer	0.000157	0.00109	CcSEcCtD
Loperamide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000157	0.00109	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000155	0.00107	CcSEcCtD
Loperamide—Loss of consciousness—Etoposide—prostate cancer	0.000154	0.00106	CcSEcCtD
Loperamide—Dizziness—Goserelin—prostate cancer	0.000153	0.00106	CcSEcCtD
Loperamide—Erythema multiforme—Capecitabine—prostate cancer	0.000153	0.00105	CcSEcCtD
Loperamide—Somnolence—Mitoxantrone—prostate cancer	0.000152	0.00105	CcSEcCtD
Loperamide—Dizziness—Conjugated Estrogens—prostate cancer	0.000152	0.00105	CcSEcCtD
Loperamide—Dyspepsia—Mitoxantrone—prostate cancer	0.000151	0.00104	CcSEcCtD
Loperamide—Immune system disorder—Docetaxel—prostate cancer	0.000151	0.00104	CcSEcCtD
Loperamide—Gastrointestinal pain—Estradiol—prostate cancer	0.00015	0.00104	CcSEcCtD
Loperamide—Abdominal pain upper—Epirubicin—prostate cancer	0.000148	0.00102	CcSEcCtD
Loperamide—Fatigue—Mitoxantrone—prostate cancer	0.000148	0.00102	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000148	0.00102	CcSEcCtD
Loperamide—Vomiting—Goserelin—prostate cancer	0.000148	0.00102	CcSEcCtD
Loperamide—Discomfort—Etoposide—prostate cancer	0.000147	0.00101	CcSEcCtD
Loperamide—Constipation—Mitoxantrone—prostate cancer	0.000147	0.00101	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Rash—Goserelin—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Dermatitis—Goserelin—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Vomiting—Conjugated Estrogens—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Urticaria—Estradiol—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Immune system disorder—Capecitabine—prostate cancer	0.000146	0.00101	CcSEcCtD
Loperamide—Abdominal pain—Estradiol—prostate cancer	0.000145	0.001	CcSEcCtD
Loperamide—Headache—Goserelin—prostate cancer	0.000145	0.001	CcSEcCtD
Loperamide—Rash—Conjugated Estrogens—prostate cancer	0.000145	0.001	CcSEcCtD
Loperamide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000145	0.000999	CcSEcCtD
Loperamide—Headache—Conjugated Estrogens—prostate cancer	0.000144	0.000994	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—prostate cancer	0.000143	0.000984	CcSEcCtD
Loperamide—ABCB1—lymph node—prostate cancer	0.000142	0.00254	CbGeAlD
Loperamide—Abdominal distension—Epirubicin—prostate cancer	0.000141	0.000976	CcSEcCtD
Loperamide—Toremifene—CYP1A1—prostate cancer	0.000141	0.0316	CrCbGaD
Loperamide—Levomethadyl Acetate—CYP3A5—prostate cancer	0.000141	0.0315	CrCbGaD
Loperamide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.00014	0.000967	CcSEcCtD
Loperamide—Flatulence—Capecitabine—prostate cancer	0.000138	0.000956	CcSEcCtD
Loperamide—Skin disorder—Etoposide—prostate cancer	0.000138	0.000956	CcSEcCtD
Loperamide—Nausea—Goserelin—prostate cancer	0.000138	0.000951	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—prostate cancer	0.000137	0.000948	CcSEcCtD
Loperamide—Nausea—Conjugated Estrogens—prostate cancer	0.000136	0.000942	CcSEcCtD
Loperamide—Clotrimazole—CYP2A6—prostate cancer	0.000136	0.0304	CrCbGaD
Loperamide—Urticaria—Mitoxantrone—prostate cancer	0.000136	0.00094	CcSEcCtD
Loperamide—Hypersensitivity—Estradiol—prostate cancer	0.000135	0.000935	CcSEcCtD
Loperamide—Abdominal pain—Mitoxantrone—prostate cancer	0.000135	0.000935	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000135	0.000935	CcSEcCtD
Loperamide—Asthenia—Estradiol—prostate cancer	0.000132	0.000911	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—prostate cancer	0.000131	0.000903	CcSEcCtD
Loperamide—Pruritus—Estradiol—prostate cancer	0.00013	0.000898	CcSEcCtD
Loperamide—Immune system disorder—Prednisone—prostate cancer	0.00013	0.000897	CcSEcCtD
Loperamide—Levomethadyl Acetate—CYP19A1—prostate cancer	0.00013	0.029	CrCbGaD
Loperamide—Clotrimazole—CYP19A1—prostate cancer	0.00013	0.029	CrCbGaD
Loperamide—Loss of consciousness—Docetaxel—prostate cancer	0.000128	0.000881	CcSEcCtD
Loperamide—Haloperidol—CYP3A5—prostate cancer	0.000127	0.0283	CrCbGaD
Loperamide—Somnolence—Etoposide—prostate cancer	0.000127	0.000875	CcSEcCtD
Loperamide—Hypersensitivity—Mitoxantrone—prostate cancer	0.000126	0.000872	CcSEcCtD
Loperamide—Diarrhoea—Estradiol—prostate cancer	0.000126	0.000869	CcSEcCtD
Loperamide—Methadone—CYP2C18—prostate cancer	0.000125	0.028	CrCbGaD
Loperamide—Drowsiness—Epirubicin—prostate cancer	0.000125	0.000865	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000124	0.000857	CcSEcCtD
Loperamide—Loss of consciousness—Capecitabine—prostate cancer	0.000124	0.000853	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—prostate cancer	0.000123	0.000849	CcSEcCtD
Loperamide—Asthenia—Mitoxantrone—prostate cancer	0.000123	0.000849	CcSEcCtD
Loperamide—Fatigue—Etoposide—prostate cancer	0.000123	0.000848	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000123	0.000847	CcSEcCtD
Loperamide—Constipation—Etoposide—prostate cancer	0.000122	0.000841	CcSEcCtD
Loperamide—Dizziness—Estradiol—prostate cancer	0.000122	0.00084	CcSEcCtD
Loperamide—Dry mouth—Docetaxel—prostate cancer	0.000121	0.000834	CcSEcCtD
Loperamide—Fentanyl—CYP3A5—prostate cancer	0.00012	0.0269	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000119	0.00082	CcSEcCtD
Loperamide—Anaphylactic shock—Docetaxel—prostate cancer	0.000118	0.000818	CcSEcCtD
Loperamide—Discomfort—Capecitabine—prostate cancer	0.000118	0.000816	CcSEcCtD
Loperamide—Diarrhoea—Mitoxantrone—prostate cancer	0.000117	0.000809	CcSEcCtD
Loperamide—Dry mouth—Capecitabine—prostate cancer	0.000117	0.000808	CcSEcCtD
Loperamide—Vomiting—Estradiol—prostate cancer	0.000117	0.000807	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—prostate cancer	0.000117	0.000805	CcSEcCtD
Loperamide—Nervous system disorder—Docetaxel—prostate cancer	0.000116	0.000802	CcSEcCtD
Loperamide—Rash—Estradiol—prostate cancer	0.000116	0.0008	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—prostate cancer	0.000116	0.0008	CcSEcCtD
Loperamide—Dermatitis—Estradiol—prostate cancer	0.000116	0.0008	CcSEcCtD
Loperamide—Headache—Estradiol—prostate cancer	0.000115	0.000795	CcSEcCtD
Loperamide—Skin disorder—Docetaxel—prostate cancer	0.000115	0.000794	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000115	0.000793	CcSEcCtD
Loperamide—Tamoxifen—ESR2—prostate cancer	0.000115	0.0256	CrCbGaD
Loperamide—Angioedema—Prednisone—prostate cancer	0.000114	0.00079	CcSEcCtD
Loperamide—Clemastine—CYP3A4—prostate cancer	0.000114	0.0254	CrCbGaD
Loperamide—Urticaria—Etoposide—prostate cancer	0.000113	0.000782	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—prostate cancer	0.000113	0.000778	CcSEcCtD
Loperamide—Nervous system disorder—Capecitabine—prostate cancer	0.000112	0.000776	CcSEcCtD
Loperamide—Skin disorder—Capecitabine—prostate cancer	0.000111	0.000769	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—prostate cancer	0.000111	0.000767	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—prostate cancer	0.00011	0.000761	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—prostate cancer	0.00011	0.000759	CcSEcCtD
Loperamide—Nausea—Estradiol—prostate cancer	0.000109	0.000754	CcSEcCtD
Loperamide—Vomiting—Mitoxantrone—prostate cancer	0.000109	0.000752	CcSEcCtD
Loperamide—Rash—Mitoxantrone—prostate cancer	0.000108	0.000746	CcSEcCtD
Loperamide—Dermatitis—Mitoxantrone—prostate cancer	0.000108	0.000745	CcSEcCtD
Loperamide—Headache—Mitoxantrone—prostate cancer	0.000107	0.000741	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—prostate cancer	0.000106	0.000734	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000106	0.000731	CcSEcCtD
Loperamide—Somnolence—Docetaxel—prostate cancer	0.000105	0.000727	CcSEcCtD
Loperamide—Discomfort—Prednisone—prostate cancer	0.000105	0.000727	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—prostate cancer	0.000105	0.000725	CcSEcCtD
Loperamide—Tamoxifen—CYP1B1—prostate cancer	0.000105	0.0234	CrCbGaD
Loperamide—Dyspepsia—Docetaxel—prostate cancer	0.000104	0.00072	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—prostate cancer	0.000103	0.000709	CcSEcCtD
Loperamide—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000102	0.000706	CcSEcCtD
Loperamide—Asthenia—Etoposide—prostate cancer	0.000102	0.000706	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—prostate cancer	0.000102	0.000705	CcSEcCtD
Loperamide—Fatigue—Docetaxel—prostate cancer	0.000102	0.000705	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—prostate cancer	0.000102	0.000704	CcSEcCtD
Loperamide—Nausea—Mitoxantrone—prostate cancer	0.000102	0.000703	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—prostate cancer	0.000102	0.000701	CcSEcCtD
Loperamide—Constipation—Docetaxel—prostate cancer	0.000101	0.000699	CcSEcCtD
Loperamide—Dyspepsia—Capecitabine—prostate cancer	0.000101	0.000697	CcSEcCtD
Loperamide—Pruritus—Etoposide—prostate cancer	0.000101	0.000696	CcSEcCtD
Loperamide—Nervous system disorder—Prednisone—prostate cancer	0.0001	0.000692	CcSEcCtD
Loperamide—Skin disorder—Prednisone—prostate cancer	9.92e-05	0.000685	CcSEcCtD
Loperamide—Gastrointestinal disorder—Capecitabine—prostate cancer	9.9e-05	0.000684	CcSEcCtD
Loperamide—Fatigue—Capecitabine—prostate cancer	9.89e-05	0.000683	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—prostate cancer	9.84e-05	0.000679	CcSEcCtD
Loperamide—Constipation—Capecitabine—prostate cancer	9.81e-05	0.000677	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—prostate cancer	9.75e-05	0.000673	CcSEcCtD
Loperamide—Gastrointestinal pain—Docetaxel—prostate cancer	9.69e-05	0.000669	CcSEcCtD
Loperamide—Clotrimazole—CYP2E1—prostate cancer	9.68e-05	0.0216	CrCbGaD
Loperamide—Flatulence—Epirubicin—prostate cancer	9.65e-05	0.000666	CcSEcCtD
Loperamide—Clotrimazole—CYP2C19—prostate cancer	9.59e-05	0.0214	CrCbGaD
Loperamide—Dizziness—Etoposide—prostate cancer	9.43e-05	0.000651	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—prostate cancer	9.4e-05	0.000649	CcSEcCtD
Loperamide—Gastrointestinal pain—Capecitabine—prostate cancer	9.38e-05	0.000647	CcSEcCtD
Loperamide—Abdominal pain—Docetaxel—prostate cancer	9.36e-05	0.000646	CcSEcCtD
Loperamide—Urticaria—Capecitabine—prostate cancer	9.11e-05	0.000629	CcSEcCtD
Loperamide—Abdominal pain—Capecitabine—prostate cancer	9.07e-05	0.000626	CcSEcCtD
Loperamide—Vomiting—Etoposide—prostate cancer	9.06e-05	0.000626	CcSEcCtD
Loperamide—Toremifene—CYP3A4—prostate cancer	9.03e-05	0.0202	CrCbGaD
Loperamide—Dyspepsia—Prednisone—prostate cancer	8.99e-05	0.000621	CcSEcCtD
Loperamide—Rash—Etoposide—prostate cancer	8.99e-05	0.00062	CcSEcCtD
Loperamide—Dermatitis—Etoposide—prostate cancer	8.98e-05	0.00062	CcSEcCtD
Loperamide—Headache—Etoposide—prostate cancer	8.93e-05	0.000616	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—prostate cancer	8.93e-05	0.000616	CcSEcCtD
Loperamide—Fatigue—Prednisone—prostate cancer	8.81e-05	0.000608	CcSEcCtD
Loperamide—Constipation—Prednisone—prostate cancer	8.74e-05	0.000603	CcSEcCtD
Loperamide—Hypersensitivity—Docetaxel—prostate cancer	8.73e-05	0.000602	CcSEcCtD
Loperamide—Haloperidol—CYP2C19—prostate cancer	8.63e-05	0.0193	CrCbGaD
Loperamide—Loss of consciousness—Epirubicin—prostate cancer	8.6e-05	0.000594	CcSEcCtD
Loperamide—Haloperidol—CYP1A1—prostate cancer	8.6e-05	0.0192	CrCbGaD
Loperamide—Asthenia—Docetaxel—prostate cancer	8.5e-05	0.000587	CcSEcCtD
Loperamide—Nausea—Etoposide—prostate cancer	8.47e-05	0.000584	CcSEcCtD
Loperamide—Hypersensitivity—Capecitabine—prostate cancer	8.45e-05	0.000583	CcSEcCtD
Loperamide—Pruritus—Docetaxel—prostate cancer	8.38e-05	0.000579	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—prostate cancer	8.35e-05	0.000577	CcSEcCtD
Loperamide—Tamoxifen—CYP3A5—prostate cancer	8.33e-05	0.0186	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	8.28e-05	0.000571	CcSEcCtD
Loperamide—Methadone—CYP3A5—prostate cancer	8.26e-05	0.0184	CrCbGaD
Loperamide—Discomfort—Epirubicin—prostate cancer	8.23e-05	0.000568	CcSEcCtD
Loperamide—Asthenia—Capecitabine—prostate cancer	8.23e-05	0.000568	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—prostate cancer	8.15e-05	0.000563	CcSEcCtD
Loperamide—Urticaria—Prednisone—prostate cancer	8.12e-05	0.00056	CcSEcCtD
Loperamide—Pruritus—Capecitabine—prostate cancer	8.11e-05	0.00056	CcSEcCtD
Loperamide—Darifenacin—CYP3A4—prostate cancer	8.11e-05	0.0181	CrCbGaD
Loperamide—Diarrhoea—Docetaxel—prostate cancer	8.11e-05	0.00056	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—prostate cancer	8.08e-05	0.000557	CcSEcCtD
Loperamide—Tamoxifen—CYP2A6—prostate cancer	8.06e-05	0.018	CrCbGaD
Loperamide—Anaphylactic shock—Epirubicin—prostate cancer	7.99e-05	0.000552	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—prostate cancer	7.96e-05	0.00055	CcSEcCtD
Loperamide—Diarrhoea—Capecitabine—prostate cancer	7.85e-05	0.000542	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—prostate cancer	7.84e-05	0.000541	CcSEcCtD
Loperamide—Dizziness—Docetaxel—prostate cancer	7.83e-05	0.000541	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—prostate cancer	7.76e-05	0.000536	CcSEcCtD
Loperamide—Tamoxifen—CYP19A1—prostate cancer	7.67e-05	0.0171	CrCbGaD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	7.66e-05	0.000529	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—prostate cancer	7.62e-05	0.000526	CcSEcCtD
Loperamide—Methadone—CYP19A1—prostate cancer	7.61e-05	0.017	CrCbGaD
Loperamide—Dizziness—Capecitabine—prostate cancer	7.58e-05	0.000524	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—prostate cancer	7.54e-05	0.000521	CcSEcCtD
Loperamide—Vomiting—Docetaxel—prostate cancer	7.53e-05	0.00052	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—prostate cancer	7.53e-05	0.00052	CcSEcCtD
Loperamide—Rash—Docetaxel—prostate cancer	7.47e-05	0.000516	CcSEcCtD
Loperamide—Dermatitis—Docetaxel—prostate cancer	7.46e-05	0.000515	CcSEcCtD
Loperamide—Headache—Docetaxel—prostate cancer	7.42e-05	0.000512	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—prostate cancer	7.39e-05	0.00051	CcSEcCtD
Loperamide—Asthenia—Prednisone—prostate cancer	7.33e-05	0.000506	CcSEcCtD
Loperamide—Vomiting—Capecitabine—prostate cancer	7.29e-05	0.000503	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—prostate cancer	7.25e-05	0.0005	CcSEcCtD
Loperamide—Rash—Capecitabine—prostate cancer	7.23e-05	0.000499	CcSEcCtD
Loperamide—Pruritus—Prednisone—prostate cancer	7.23e-05	0.000499	CcSEcCtD
Loperamide—Dermatitis—Capecitabine—prostate cancer	7.22e-05	0.000499	CcSEcCtD
Loperamide—Headache—Capecitabine—prostate cancer	7.18e-05	0.000496	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—prostate cancer	7.18e-05	0.000496	CcSEcCtD
Loperamide—Somnolence—Epirubicin—prostate cancer	7.1e-05	0.00049	CcSEcCtD
Loperamide—Tamoxifen—ESR1—prostate cancer	7.06e-05	0.0158	CrCbGaD
Loperamide—Nausea—Docetaxel—prostate cancer	7.04e-05	0.000486	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—prostate cancer	7.03e-05	0.000486	CcSEcCtD
Loperamide—Diarrhoea—Prednisone—prostate cancer	6.99e-05	0.000483	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—prostate cancer	6.9e-05	0.000476	CcSEcCtD
Loperamide—Fatigue—Epirubicin—prostate cancer	6.89e-05	0.000476	CcSEcCtD
Loperamide—Constipation—Epirubicin—prostate cancer	6.83e-05	0.000472	CcSEcCtD
Loperamide—Nausea—Capecitabine—prostate cancer	6.81e-05	0.00047	CcSEcCtD
Loperamide—Dizziness—Prednisone—prostate cancer	6.76e-05	0.000466	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—prostate cancer	6.57e-05	0.000454	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—prostate cancer	6.53e-05	0.000451	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—prostate cancer	6.51e-05	0.000449	CcSEcCtD
Loperamide—Vomiting—Prednisone—prostate cancer	6.5e-05	0.000448	CcSEcCtD
Loperamide—Rash—Prednisone—prostate cancer	6.44e-05	0.000445	CcSEcCtD
Loperamide—Dermatitis—Prednisone—prostate cancer	6.44e-05	0.000444	CcSEcCtD
Loperamide—Headache—Prednisone—prostate cancer	6.4e-05	0.000442	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.38e-05	0.000441	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—prostate cancer	6.37e-05	0.00044	CcSEcCtD
Loperamide—Urticaria—Epirubicin—prostate cancer	6.35e-05	0.000438	CcSEcCtD
Loperamide—Constipation—Doxorubicin—prostate cancer	6.32e-05	0.000436	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—prostate cancer	6.32e-05	0.000436	CcSEcCtD
Loperamide—Levomethadyl Acetate—CYP3A4—prostate cancer	6.1e-05	0.0136	CrCbGaD
Loperamide—Clotrimazole—CYP3A4—prostate cancer	6.1e-05	0.0136	CrCbGaD
Loperamide—Nausea—Prednisone—prostate cancer	6.07e-05	0.000419	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—prostate cancer	6.05e-05	0.000417	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—prostate cancer	5.89e-05	0.000406	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—prostate cancer	5.87e-05	0.000405	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—prostate cancer	5.84e-05	0.000403	CcSEcCtD
Loperamide—Asthenia—Epirubicin—prostate cancer	5.73e-05	0.000396	CcSEcCtD
Loperamide—Tamoxifen—CYP2E1—prostate cancer	5.72e-05	0.0128	CrCbGaD
Loperamide—Tamoxifen—CYP2C19—prostate cancer	5.67e-05	0.0127	CrCbGaD
Loperamide—Pruritus—Epirubicin—prostate cancer	5.65e-05	0.00039	CcSEcCtD
Loperamide—Tamoxifen—CYP1A1—prostate cancer	5.65e-05	0.0126	CrCbGaD
Loperamide—Methadone—CYP2C19—prostate cancer	5.62e-05	0.0126	CrCbGaD
Loperamide—Haloperidol—CYP3A4—prostate cancer	5.49e-05	0.0123	CrCbGaD
Loperamide—Diarrhoea—Epirubicin—prostate cancer	5.47e-05	0.000377	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—prostate cancer	5.45e-05	0.000376	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—prostate cancer	5.3e-05	0.000366	CcSEcCtD
Loperamide—Dizziness—Epirubicin—prostate cancer	5.28e-05	0.000365	CcSEcCtD
Loperamide—Dextropropoxyphene—CYP3A4—prostate cancer	5.27e-05	0.0118	CrCbGaD
Loperamide—Pruritus—Doxorubicin—prostate cancer	5.23e-05	0.000361	CcSEcCtD
Loperamide—Fentanyl—CYP3A4—prostate cancer	5.21e-05	0.0116	CrCbGaD
Loperamide—Vomiting—Epirubicin—prostate cancer	5.08e-05	0.000351	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—prostate cancer	5.06e-05	0.000349	CcSEcCtD
Loperamide—Rash—Epirubicin—prostate cancer	5.04e-05	0.000348	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—prostate cancer	5.03e-05	0.000347	CcSEcCtD
Loperamide—Headache—Epirubicin—prostate cancer	5.01e-05	0.000346	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—prostate cancer	4.89e-05	0.000337	CcSEcCtD
Loperamide—Nausea—Epirubicin—prostate cancer	4.75e-05	0.000328	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—prostate cancer	4.7e-05	0.000324	CcSEcCtD
Loperamide—Rash—Doxorubicin—prostate cancer	4.66e-05	0.000322	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—prostate cancer	4.66e-05	0.000321	CcSEcCtD
Loperamide—Headache—Doxorubicin—prostate cancer	4.63e-05	0.00032	CcSEcCtD
Loperamide—Nausea—Doxorubicin—prostate cancer	4.39e-05	0.000303	CcSEcCtD
Loperamide—Tamoxifen—CYP3A4—prostate cancer	3.6e-05	0.00805	CrCbGaD
Loperamide—Methadone—CYP3A4—prostate cancer	3.57e-05	0.00798	CrCbGaD
Loperamide—CALM3—Signaling Pathways—IGF1—prostate cancer	1.32e-06	6.96e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—PTEN—prostate cancer	1.32e-06	6.95e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—PTEN—prostate cancer	1.32e-06	6.95e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.32e-06	6.95e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—prostate cancer	1.32e-06	6.92e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GGT1—prostate cancer	1.32e-06	6.92e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTGS2—prostate cancer	1.31e-06	6.9e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CG—prostate cancer	1.31e-06	6.89e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—prostate cancer	1.3e-06	6.85e-06	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—prostate cancer	1.3e-06	6.85e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NCOA1—prostate cancer	1.3e-06	6.82e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CREBBP—prostate cancer	1.3e-06	6.82e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CREBBP—prostate cancer	1.3e-06	6.82e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	1.29e-06	6.78e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—prostate cancer	1.28e-06	6.75e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—prostate cancer	1.28e-06	6.74e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CB—prostate cancer	1.28e-06	6.74e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CB—prostate cancer	1.28e-06	6.74e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—prostate cancer	1.28e-06	6.73e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—prostate cancer	1.28e-06	6.73e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1—prostate cancer	1.28e-06	6.73e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1—prostate cancer	1.28e-06	6.73e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAP2K1—prostate cancer	1.28e-06	6.72e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.28e-06	6.72e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—prostate cancer	1.27e-06	6.7e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—prostate cancer	1.27e-06	6.7e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CD—prostate cancer	1.27e-06	6.68e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTGS2—prostate cancer	1.27e-06	6.67e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTGS2—prostate cancer	1.27e-06	6.67e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—prostate cancer	1.27e-06	6.66e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—prostate cancer	1.26e-06	6.63e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—prostate cancer	1.26e-06	6.63e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SERPINE1—prostate cancer	1.26e-06	6.61e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—prostate cancer	1.26e-06	6.61e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—prostate cancer	1.25e-06	6.56e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—NOS3—prostate cancer	1.25e-06	6.56e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—prostate cancer	1.24e-06	6.54e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—INS—prostate cancer	1.24e-06	6.52e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAP2K1—prostate cancer	1.24e-06	6.51e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAP2K1—prostate cancer	1.24e-06	6.51e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.23e-06	6.49e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RXRA—prostate cancer	1.23e-06	6.49e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CD—prostate cancer	1.23e-06	6.46e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CD—prostate cancer	1.23e-06	6.46e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—prostate cancer	1.23e-06	6.45e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—prostate cancer	1.23e-06	6.45e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—prostate cancer	1.22e-06	6.43e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGF2—prostate cancer	1.22e-06	6.4e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SERPINE1—prostate cancer	1.21e-06	6.39e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SERPINE1—prostate cancer	1.21e-06	6.39e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CREBBP—prostate cancer	1.21e-06	6.39e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—prostate cancer	1.2e-06	6.33e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—prostate cancer	1.2e-06	6.33e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—prostate cancer	1.2e-06	6.33e-06	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—prostate cancer	1.2e-06	6.32e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NOS3—prostate cancer	1.2e-06	6.31e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—COMT—prostate cancer	1.19e-06	6.25e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—prostate cancer	1.19e-06	6.24e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—prostate cancer	1.18e-06	6.22e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—prostate cancer	1.18e-06	6.22e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—prostate cancer	1.18e-06	6.22e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGF2—prostate cancer	1.18e-06	6.19e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGF2—prostate cancer	1.18e-06	6.19e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—prostate cancer	1.18e-06	6.18e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—INS—prostate cancer	1.17e-06	6.14e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JAK2—prostate cancer	1.17e-06	6.13e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—prostate cancer	1.16e-06	6.12e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—prostate cancer	1.16e-06	6.12e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ITPR1—prostate cancer	1.16e-06	6.12e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NOS3—prostate cancer	1.16e-06	6.1e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NOS3—prostate cancer	1.16e-06	6.1e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.15e-06	6.06e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CD—prostate cancer	1.15e-06	6.05e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CREBBP—prostate cancer	1.14e-06	6.02e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—prostate cancer	1.14e-06	6.02e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—prostate cancer	1.14e-06	6.01e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—prostate cancer	1.14e-06	6.01e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTGS2—prostate cancer	1.14e-06	6e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—prostate cancer	1.14e-06	5.98e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—prostate cancer	1.14e-06	5.98e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—prostate cancer	1.14e-06	5.97e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—prostate cancer	1.13e-06	5.96e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JAK2—prostate cancer	1.13e-06	5.93e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JAK2—prostate cancer	1.13e-06	5.93e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ERBB2—prostate cancer	1.12e-06	5.9e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—prostate cancer	1.12e-06	5.9e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—prostate cancer	1.11e-06	5.84e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CB—prostate cancer	1.11e-06	5.82e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—prostate cancer	1.11e-06	5.82e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—prostate cancer	1.11e-06	5.82e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—prostate cancer	1.1e-06	5.81e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—prostate cancer	1.1e-06	5.81e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—prostate cancer	1.1e-06	5.79e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—prostate cancer	1.1e-06	5.79e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TYMS—prostate cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—prostate cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—prostate cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—prostate cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—prostate cancer	1.1e-06	5.78e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—prostate cancer	1.1e-06	5.76e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—prostate cancer	1.1e-06	5.76e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—prostate cancer	1.09e-06	5.74e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	1.09e-06	5.73e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—NOS3—prostate cancer	1.09e-06	5.72e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—prostate cancer	1.09e-06	5.71e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ERBB2—prostate cancer	1.08e-06	5.71e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ERBB2—prostate cancer	1.08e-06	5.71e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.08e-06	5.71e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—prostate cancer	1.07e-06	5.65e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—prostate cancer	1.07e-06	5.65e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CB—prostate cancer	1.07e-06	5.63e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CB—prostate cancer	1.07e-06	5.63e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—LPL—prostate cancer	1.07e-06	5.61e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL8—prostate cancer	1.06e-06	5.6e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—prostate cancer	1.06e-06	5.55e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—prostate cancer	1.06e-06	5.55e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—prostate cancer	1.05e-06	5.55e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—prostate cancer	1.05e-06	5.54e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—prostate cancer	1.05e-06	5.52e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—prostate cancer	1.04e-06	5.49e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1B—prostate cancer	1.04e-06	5.46e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.03e-06	5.42e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL8—prostate cancer	1.03e-06	5.41e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL8—prostate cancer	1.03e-06	5.41e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—NOS3—prostate cancer	1.02e-06	5.39e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ERCC2—prostate cancer	1.02e-06	5.37e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—prostate cancer	1.02e-06	5.36e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—prostate cancer	1.02e-06	5.35e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—prostate cancer	1.01e-06	5.34e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—prostate cancer	1.01e-06	5.34e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—prostate cancer	1.01e-06	5.32e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—prostate cancer	1.01e-06	5.31e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—prostate cancer	1.01e-06	5.31e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1B—prostate cancer	1e-06	5.29e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1B—prostate cancer	1e-06	5.29e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CB—prostate cancer	1e-06	5.28e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—prostate cancer	9.95e-07	5.23e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTGS2—prostate cancer	9.94e-07	5.23e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—prostate cancer	9.91e-07	5.21e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—prostate cancer	9.85e-07	5.18e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—prostate cancer	9.85e-07	5.18e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—prostate cancer	9.83e-07	5.17e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—prostate cancer	9.83e-07	5.17e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—prostate cancer	9.81e-07	5.16e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—prostate cancer	9.78e-07	5.15e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—prostate cancer	9.78e-07	5.15e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—prostate cancer	9.65e-07	5.08e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—prostate cancer	9.64e-07	5.07e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—prostate cancer	9.62e-07	5.06e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—prostate cancer	9.6e-07	5.05e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1A—prostate cancer	9.59e-07	5.04e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—prostate cancer	9.59e-07	5.04e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—prostate cancer	9.59e-07	5.04e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—prostate cancer	9.56e-07	5.03e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—prostate cancer	9.49e-07	4.99e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—prostate cancer	9.49e-07	4.99e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—prostate cancer	9.49e-07	4.99e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CB—prostate cancer	9.45e-07	4.97e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PPARA—prostate cancer	9.42e-07	4.95e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTGS2—prostate cancer	9.37e-07	4.93e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—prostate cancer	9.33e-07	4.91e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—prostate cancer	9.32e-07	4.9e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—prostate cancer	9.32e-07	4.9e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—prostate cancer	9.31e-07	4.9e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—prostate cancer	9.31e-07	4.9e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1A—prostate cancer	9.27e-07	4.88e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1A—prostate cancer	9.27e-07	4.88e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—prostate cancer	9.25e-07	4.87e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—prostate cancer	9.25e-07	4.87e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—prostate cancer	9.24e-07	4.86e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—prostate cancer	9.12e-07	4.8e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—prostate cancer	9.03e-07	4.75e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—prostate cancer	9.03e-07	4.75e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—prostate cancer	8.94e-07	4.7e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—prostate cancer	8.94e-07	4.7e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—prostate cancer	8.9e-07	4.68e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—prostate cancer	8.87e-07	4.67e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CAV1—prostate cancer	8.86e-07	4.66e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—prostate cancer	8.82e-07	4.64e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—prostate cancer	8.82e-07	4.64e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—prostate cancer	8.67e-07	4.56e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—prostate cancer	8.64e-07	4.54e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—prostate cancer	8.58e-07	4.51e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—prostate cancer	8.58e-07	4.51e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—prostate cancer	8.55e-07	4.5e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—prostate cancer	8.53e-07	4.49e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—prostate cancer	8.53e-07	4.48e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—prostate cancer	8.36e-07	4.4e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—prostate cancer	8.36e-07	4.4e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—prostate cancer	8.29e-07	4.36e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—prostate cancer	8.27e-07	4.35e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—prostate cancer	8.27e-07	4.35e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—prostate cancer	8.27e-07	4.35e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—prostate cancer	8.25e-07	4.34e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—prostate cancer	8.25e-07	4.34e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—prostate cancer	8.25e-07	4.34e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—prostate cancer	8.25e-07	4.34e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—prostate cancer	8.17e-07	4.3e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—prostate cancer	8.07e-07	4.25e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.07e-07	4.24e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—prostate cancer	7.95e-07	4.18e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—prostate cancer	7.93e-07	4.17e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—prostate cancer	7.87e-07	4.14e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—prostate cancer	7.81e-07	4.11e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—prostate cancer	7.81e-07	4.11e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—prostate cancer	7.79e-07	4.1e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—prostate cancer	7.77e-07	4.09e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—prostate cancer	7.69e-07	4.04e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—prostate cancer	7.69e-07	4.04e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—prostate cancer	7.67e-07	4.03e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—prostate cancer	7.67e-07	4.03e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—INS—prostate cancer	7.64e-07	4.02e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—prostate cancer	7.61e-07	4.01e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—prostate cancer	7.61e-07	4.01e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—prostate cancer	7.52e-07	3.96e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—prostate cancer	7.52e-07	3.96e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CREBBP—prostate cancer	7.48e-07	3.93e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—prostate cancer	7.34e-07	3.86e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—prostate cancer	7.1e-07	3.74e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—prostate cancer	7.1e-07	3.74e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.09e-07	3.73e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—prostate cancer	7.02e-07	3.69e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—prostate cancer	6.77e-07	3.56e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—prostate cancer	6.75e-07	3.55e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NOS3—prostate cancer	6.7e-07	3.52e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—prostate cancer	6.59e-07	3.47e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—prostate cancer	6.53e-07	3.43e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—prostate cancer	6.53e-07	3.43e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—prostate cancer	6.53e-07	3.43e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—prostate cancer	6.38e-07	3.35e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—prostate cancer	6.38e-07	3.35e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—prostate cancer	6.31e-07	3.32e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—prostate cancer	6.31e-07	3.32e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.18e-07	3.25e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTGS2—prostate cancer	6.12e-07	3.22e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—prostate cancer	6.12e-07	3.22e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—prostate cancer	5.97e-07	3.14e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—prostate cancer	5.78e-07	3.04e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—prostate cancer	5.78e-07	3.04e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.76e-07	3.03e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—prostate cancer	5.73e-07	3.02e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—prostate cancer	5.51e-07	2.9e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—prostate cancer	5.34e-07	2.81e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—prostate cancer	5.33e-07	2.81e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—prostate cancer	5.33e-07	2.81e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—prostate cancer	5.09e-07	2.68e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—prostate cancer	5e-07	2.63e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—prostate cancer	4.71e-07	2.48e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.77e-07	1.98e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—prostate cancer	3.08e-07	1.62e-06	CbGpPWpGaD
